An observational study in Young Onset Parkinson Disease and Parkinson Disease, sponsored by NYU Langone Health. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by NYU Langone Health · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Parkinson Disease by NYU Langone Health — 3 open to participants now, 3 under way, none of them phase 3. Parkinson Disease · NYU Langone Health.
Among the 16 studies in Parkinson Disease by NYU Langone Health, this one is the only one that started in 2024, is one of 6 observational ones, and was the 15th registered.
4,576 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →3 of the 16 studies in Parkinson Disease by NYU Langone Health are open now, in 4 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18–90 · Healthy volunteers
NYU Langone Health · Sites in United States, Argentina, Korea, Republic of and 1 more country
Ages 18+
By country, each count listing its studies:
Of the 749 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 96 across 1,086 observational studies indexed under Parkinson Disease.
Median enrollment 21 across the 10 interventional studies, 200 across the 6 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
NYU Langone Health is the lead sponsor of 1,430 studies on the registry; 258 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
1 of the studies in Parkinson Disease by NYU Langone Health that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01799915NYU Langone HealthNatural History Study of Synucleinopathies | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Parkinson Disease by NYU Langone Health, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Young Onset Parkinson's disease (YOPD) refers to a group of patients in which the disease starts earlier in life (before the age of 50 years) and has a profound impact on most of patient's life. Current knowledge regarding the mechanisms leading to development of Parkinson's disease in younger individuals is lacking, but their understanding is crucial for the successful design of therapeutic strategies and stratifying patients for clinical trials. With this research the investigators aim to clarify the contribution of relevant biological processes in patients with Young onset Parkinson's disease to help understanding disease mechanisms and biomarkers.
With the present project the investigators propose to study clinical and biological data (from peripheral blood and skin punch biopsy) in subjects with Young and Late Onset Parkinson's disease as well as non-affected subjects (controls) to identify characteristic biological traits for each for this groups.
For each participant, the investigators will collect information about demographic data, clinical data related to the symptoms of Parkinson's disease through standard questionnaire, a clinical exam, and standard interview. A blood sample (from a peripheral vein) and skin punch biopsy will be collected to study genetic and biological markers of the disease. The study duration for each participant is of one in-person visit at the study center.
In a subgroup of subjects, biological data from the lumbar puncture will be collected and analyzed as well.
4,576 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
This study's planned enrollment of 250 is above the median of 96 across 1,086 observational studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →NYU Langone Health is the lead sponsor of 1,430 studies on the registry; 258 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
Compared within Parkinson Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Parkinsonian Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Male or Female subjects with Parkinson disease and non-affected subjects 18 years of age or older.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
YOPD cohort:
LOPD cohort:
Healthy Control cohort:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinical assessment: * History of PD * Medical history * Assessment of motor and non-motor symptoms of PD through standard rating scales Biological samples: * Peripheral blood sample for the study of genetic and multi-omics data * Skin punch biopsy (3mm) for the assessment of the Alpha-Synuclein seeding amplification (SAA) Assay For a sub-cohort of subjects: \- Lumbar puncture for the collection of spinal fluid for the study of biological profiles
Clinical assessment: * History of PD * Medical history * Assessment of motor and non-motor symptoms of PD through standard rating scales Biological samples: * Peripheral blood sample for the study of genetic and multi-omics data * Skin punch biopsy (3mm) for the assessment of the Alpha-Synuclein seeding amplification (SAA) Assay For a sub-cohort of subjects: Lumbar puncture for the collection of spinal fluid for the study of biological profiles
Clinical assessment: * Medical history * Assessment of motor and non-motor symptoms of PD through standard rating scales Biological samples: * Peripheral blood sample for the study of genetic and multi-omics data * Skin punch biopsy (3mm) for the assessment of the Alpha-Synuclein seeding amplification (SAA) Assay For a sub-cohort of subjects: Lumbar puncture for the collection of spinal fluid for the study of biological profiles
Alpha-Synuclein seeding amplification (SAA) Assay Results
Proportion of YOPD participants with positive of alpha-synuclein SAA in central (cerebrospinal fluid) peripheral biospecimens (skin biopsy)
Time frame: Baseline
Genetic test results
Proportion of YOPD participants with positive genetic testing for gene mutations in known PD-associated genes
Time frame: Baseline
Differences in clinical profiles
Differences of the clinical profiles related to motor and non-motor symptoms of PD in YOPD as measured by standard clinical rating scales
Time frame: Baseline
Plan to share: No — This is an Observational study that is voluntarily registered, and is not subject to mandatory results reporting under FDAAA 801/the Final Rule. This observational study is registered specifically to increase visibility and boost recruitment.
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Oct 2028, 56 months after the start.
Of 379 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 56 months is above that.
Counting every sponsor, half of 439 studies reached it within 47 months; a quarter within 22 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.